No abstract available
MeSH terms
-
Antiviral Agents / administration & dosage
-
Betacoronavirus / immunology
-
Betacoronavirus / pathogenicity*
-
COVID-19
-
COVID-19 Drug Treatment
-
Coronavirus Infections / drug therapy
-
Coronavirus Infections / immunology
-
Coronavirus Infections / therapy
-
Coronavirus Infections / transmission
-
Coronavirus Infections / virology*
-
Humans
-
Immunocompromised Host
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects
-
Kidney Transplantation / adverse effects*
-
Male
-
Middle Aged
-
Opportunistic Infections / immunology
-
Opportunistic Infections / therapy
-
Opportunistic Infections / transmission
-
Opportunistic Infections / virology*
-
Oxygen Inhalation Therapy
-
Pandemics
-
Pneumonia, Viral / immunology
-
Pneumonia, Viral / therapy
-
Pneumonia, Viral / transmission
-
Pneumonia, Viral / virology*
-
SARS-CoV-2
-
Transplant Recipients*
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Immunosuppressive Agents